Panel-derived tumor mutational burden (TMB) is associated with the response to the immune checkpoint inhibitors (ICIs) in urothelial cancers

被引：0
|
作者：
Hsieh, Yi-Lin [1 ]
Yu, Pei-Ning [1 ]
Jan, Yi-Hua [1 ]
Lai, Meng-Shao [1 ]
Wang, Woei-Fuh [1 ]
Zhuo, De-Wei [1 ]
Chen, Shu-Jen [1 ]
Cheng, Jen-Hao [1 ]
Tan, Kien Thiam [1 ]
Su, Yu-Li [2 ]
机构：
[1] ACT Genom, Taipei, Taiwan
[2] Chang Gung Mem Hosp, Kaohsiung, Taiwan
来源：
CANCER RESEARCH | 2020年 / 80卷 / 16期
关键词：
D O I：
10.1158/1538-7445.AM2020-3177
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3177
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors
    Cristina Valero
    Mark Lee
    Douglas Hoen
    Kate Weiss
    Daniel W. Kelly
    Prasad S. Adusumilli
    Paul K. Paik
    George Plitas
    Marc Ladanyi
    Michael A. Postow
    Charlotte E. Ariyan
    Alexander N. Shoushtari
    Vinod P. Balachandran
    A. Ari Hakimi
    Aimee M. Crago
    Kara C. Long Roche
    J. Joshua Smith
    Ian Ganly
    Richard J. Wong
    Snehal G. Patel
    Jatin P. Shah
    Nancy Y. Lee
    Nadeem Riaz
    Jingming Wang
    Ahmet Zehir
    Michael F. Berger
    Timothy A. Chan
    Venkatraman E. Seshan
    Luc G. T. Morris
    Nature Communications, 12
  • [22] Aluminum Concentration Is Associated with Tumor Mutational Burden and the Expression of Immune Response Biomarkers in Colorectal Cancers
    Bonfiglio, Rita
    Giacobbi, Erica
    Palumbo, Valeria
    Casciardi, Stefano
    Sisto, Renata
    Servadei, Francesca
    Scioli, Maria Paola
    Schiaroli, Stefania
    Cornella, Elena
    Cervelli, Giulio
    Sica, Giuseppe
    Candi, Eleonora
    Melino, Gerry
    Mauriello, Alessandro
    Scimeca, Manuel
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (24)
  • [23] Role of tumor mutational burden (TMB) and microsatellite instability (MSI) in patients (pts) with advanced urothelial carcinoma (aUC) treated with immune checkpoint inhibitor (ICI)
    Bakaloudi, Dimitra Rafailia
    Talukder, Rafee
    Makrakis, Dimitrios
    Diamantopoulos, Leonidas Nikolaos
    Patgunarajah, Ubenthira
    Thomas, Vinay Mathew
    Jindal, Tanya
    Brown, Jason R.
    Miletic, Marija
    Johnson, Jeffrey
    Hui, Gavin
    Buznego, Lucia Alonso
    Morales-Barrera, Rafael
    Castaneda, David Humberto Marmolejo
    Nguyen, Charles B.
    Barata, Pedro C.
    Stewart, Tyler F.
    Gupta, Shilpa
    Grivas, Petros
    Khaki, Ali Raza
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 654 - 654
  • [24] The impact of mutational clonality in predicting the response to immune checkpoint inhibitors in advanced urothelial cancer
    Boll, Lilian Marie
    Perera-Bel, Julia
    Rodriguez-Vida, Alejo
    Arpi, Oriol
    Rovira, Ana
    Juanpere, Nuria
    de Oca, Sergio Vazquez Montes
    Hernandez-Llodra, Silvia
    Lloreta, Josep
    Alba, M. Mar
    Bellmunt, Joaquim
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [25] The impact of mutational clonality in predicting the response to immune checkpoint inhibitors in advanced urothelial cancer
    Lilian Marie Boll
    Júlia Perera-Bel
    Alejo Rodriguez-Vida
    Oriol Arpí
    Ana Rovira
    Núria Juanpere
    Sergio Vázquez Montes de Oca
    Silvia Hernández-Llodrà
    Josep Lloreta
    M. Mar Albà
    Joaquim Bellmunt
    Scientific Reports, 13
  • [26] Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors
    Nassar, Amin H.
    Adib, Elio
    Alaiwi, Sarah Abou
    El Zarif, Talal
    Groha, Stefan
    Akl, Elie W.
    Nuzzo, Pier Vitale
    Mouhieddine, Tarek H.
    Perea-Chamblee, Tomin
    Taraszka, Kodi
    El-Khoury, Habib
    Labban, Muhieddine
    Fong, Christopher
    Arora, Kanika S.
    Labaki, Chris
    Xu, Wenxin
    Sonpavde, Guru
    Haddad, Robert I.
    Mouw, Kent W.
    Giannakis, Marios
    Hodi, F. Stephen
    Zaitlen, Noah
    Schoenfeld, Adam J.
    Schultz, Nikolaus
    Berger, Michael F.
    MacConaill, Laura E.
    Ananda, Guruprasad
    Kwiatkowski, David J.
    Choueiri, Toni K.
    Schrag, Deborah
    Carrot-Zhang, Jian
    Gusev, Alexander
    CANCER CELL, 2022, 40 (10) : 1161 - +
  • [27] Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer
    Schrock, A. B.
    Ouyang, C.
    Sandhu, J.
    Sokol, E.
    Jin, D.
    Ross, J. S.
    Miller, A.
    Lim, D.
    Amanam, I
    Chao, J.
    Catenacci, D.
    Cho, M.
    Braiteh, F.
    Klempner, S. J.
    Ali, S. M.
    Fakih, M.
    ANNALS OF ONCOLOGY, 2019, 30 (07) : 1096 - 1103
  • [28] Comparison of Tumor Mutational Burden (TMB) Derived from Whole Exome and Large Panel Sequencing in Lung Cancer
    Shan, G.
    Zhao, L.
    Li, L.
    Liu, B.
    Cheng, G.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2385 - S2385
  • [29] Association between tumor mutational burden (TMB) and mutational profile and its effect on overall survival: A post hoc analysis of patients with TMB-high and TMB-low metastatic cancer treated with immune checkpoint inhibitors (ICI)
    Xavier, Camila Braganca
    Guardia, Gabriela
    Lopes, Carlos Diego Holanda
    Awni, Beatriz Mendes
    Campos, Eduardo Felicio
    Alves, Joao Pedro
    Camargo, Anamaria Aranha
    Galante, Pedro Alexandre Favoretto
    Jardim, Denis L.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [30] Blood tumor mutational burden (bTMB) and efficacy of immune checkpoint inhibitors (ICIs) in advanced solid tumors: SCRUM-Japan MONSTAR-SCREEN
    Saori, M.
    Nakamura, Y.
    Sawada, K.
    Horasawa, S.
    Kadowaki, S.
    Kato, K.
    Ueno, M.
    Oki, E.
    Satoh, T.
    Komatsu, Y.
    Tukachinsky, H.
    Lee, J.
    Madison, R.
    Sokol, E.
    Pavlick, D.
    Aiyer, A.
    Fabrizio, D.
    Venstrom, J.
    Oxnard, G.
    Yoshino, T.
    ANNALS OF ONCOLOGY, 2021, 32 : S390 - S391
12345